A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment.
- EligibilityCriteria: Inclusion Criteria:  Must be 18 Years to 75 Years, both male and female. BMI ≤40 kg/m2. Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of gouty arthritis. ≥2 acute gout flares within 1 year prior to screening. Willingness to initiate urate-lowering treatment or to initiate urate-lowering treatment within 7 days prior to administration.  Exclusion Criteria:  Gout caused by radiotherapy/chemotherapy, organ transplantation, tumors, etc. Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis. Presence of severe renal function impairment. Intolerance of subcutaneous injection. Known presence or suspicion of active or recurrent bacterial, fungal, or viral infection at the time of enrollment. Live vaccinations within 8 weeks prior to the start of the study. Use of forbidden therapy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult